Dried Blood Spot Testing of CMV Detection in HCT Recipients
Key facts
- Who runs it
- National Institute of Allergy and Infectious Diseases (NIAID)
- Where
- Houston, Minneapolis, New York, and Seattle, United StatesSee the 4 sites
- Trial code
- Status
- Completed
- People taking part
- 622 people enrolled
- Started
- 3 May 2019
- Ended
- 16 Jan 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- DBS Self-Collection Kit
- Standard Control Strategy
- Record updated
- 25 February 2026
Who can take part
- Age
- 15 years to 99 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Randomized Cohort:
- Must be >/= 15 years of age at the time of enrollment
- Must be able to provide written consent and complete the informed consent
- Must have received allogeneic hematopoietic cell transplantation within 60-180 days prior to randomization
- Cytomegalovirus (CMV) seropositive or had a donor who was CMV positive
- One or both of the following:; CMV event* within the first 100 days post-transplant requiring anti-viral treatment; Receipt of CMV prophylaxis**(for at least 30 days) prior to randomization. Continuation of letermovir or acyclovir/valacyclovir (high and low dose) prophylaxis after day 100 per institutional standard of care is permitted * CMV event defined as deoxyribonucleic acid (DNA) detection or disease ** Anti-viral treatment or prophylaxis includes ganciclovir, valganciclovir, foscarnet, letermovir, maribavir or acyclovir/valacyclovir (high and low dose)
- Direct availability to the internet either by a computer in the residence or a smart phone
- Had at least one or more of these conditions:; HLA mismatch*; umbilical cord blood source**; Graft versus host disease (GVHD)***; T-cell depletion**** * Human leukocyte antigen (HLA)-related (sibling) donor with at least one mismatch at one of the following three HLA-gene loci: HLA-A, -B, or -DR, Haploidentical donor, Unrelated donor with at least one mismatch at one of the following four HLA-gene loci: HLA-A, -B, -C and -DRB1; Use of umbilical cord blood as stem cell source ***Acute or chronic GVHD requiring topical steroid for gastrointestinal (GI) GVHD and/or systemic steroid treatment (>/= 1 mg/kg/day of prednisone or equivalent dose of another corticosteroid) within 6 weeks prior to enrollment; Subjects who have received partial or full T-cell depletion (with or without GVHD). T-cell depletion can be given as either ex-vivo or in-vivo for GVHD prophylaxis. T-cell depleting agents include, but are not limited to, anti-thymocyte globulin (ATG) and alemtuzumab; Observation Cohort:
- Must be >/= 15 years of age at the time of enrollment
- Must have one of the following:; Consented for retrospective studies at their transplant center, or; Be included under the auspices of the site's IRB approved waiver of additional consent for retrospective studies
- Must have received allogeneic hematopoietic cell transplantation during or within 1 year prior to the conduct of the randomized trial (defined as time during which randomization is done)
- CMV seropositive or had a donor who was CMV positive
- One or both of the following:; CMV event* within the first 100 days post-transplant requiring anti-viral treatment; Receipt of CMV prophylaxis**(for at least 30 days) prior to registration. Continuation of letermovir prophylaxis or acyclovir/valacyclovir (high and low dose) after day 100 per institutional standard of care is permitted * CMV event defined as DNA detection or disease ** Anti-viral treatment or prophylaxis includes ganciclovir, valganciclovir, foscarnet, letermovir, maribavir or acyclovir/valacyclovir (high and low dose)
- Meet at least one or more of criteria of the following:; HLA mismatch*; umbilical cord blood source**; GVHD***; T-cell depletion****; Human leukocyte antigen (HLA)-related (sibling) donor with at least one mismatch at one of the following three HLA-gene loci: HLA-A, -B, or -DR, Haploidentical donor, Unrelated donor with at least one mismatch at one of the following four HLA-gene loci: HLA-A, -B, -C and -DRB1; Use of umbilical cord blood as stem cell source ***Acute or chronic GVHD requiring topical steroid for GI GVHD and/or systemic steroid treatment (>/= 1 mg/kg/day of prednisone or equivalent dose of another corticosteroid) within 6 weeks prior to enrollment ****Subjects who have received partial or full T-cell depletion (with or without GVHD). T-cell depletion can be given as either ex-vivo or in-vivo for GVHD prophylaxis. T-cell depleting agents include, but are not limited to, anti-thymocyte globulin (ATG) and alemtuzumab
Who cannot take part
- Morphological relapse (bone marrow or peripheral blood blast) prior to registration; Observational Cohort:
- Morphological relapse (bone marrow or peripheral blood blast) prior to registration
- Any other condition, which in the opinion of the investigator would interfere with successful completion of this clinical trial
- Randomized Cohort:
- Inability to fully comprehend the study website and study procedures
- Did not meet all inclusion criteria
Where in United States
- The University of Texas - MD Anderson Cancer Center - Infectious DiseasesHouston, United States
- University of Minnesota Medical Center, Fairview - Infectious Diseases and International MedicineMinneapolis, United States
- Memorial Sloan-Kettering Cancer CenterNew York, United States
- Fred Hutchinson Cancer Research Center - Vaccine and Infectious DiseasesSeattle, United States
About the trial
What the trial wants to find out
This is a randomized clinical trial to assess whether a subject centered, self-collection of Dried blood spots (DBS) samples will improve compliance with the clinical recommendation of weekly Cytomegalovirus (CMV) testing of Hematopoietic cell transplantation (HCT) recipients who are at high risk for late CMV disease. In this study, mobile devices will be used to remind HCT survivors to perform CMV monitoring using finger-stick collected DBS testing in their home setting or to visit their doctor's office to perform the test. 150 allogeneic HCT recipients > /= 15 years of age will be randomized (2:1) to DBS monitoring or standard of care (per local institution) monitoring. Duration of study participation is anticipated to be within a range of 26 weeks to 43 weeks. The primary objective is to evaluate adherence to recommended CMV monitoring duration and interval during the first year after HCT upon enrollment using subject collected dried blood spot testing.
The 2 groups in the trial
- Self-collected Dried Blood Spot (DBS) monitoringTreatment being tested
N=100 Subject collected DBS CMV monitoring with mobile technology support
Treatment: DBS Self-Collection Kit
- Standard Monitoring ControlExisting treatment, for comparison
N=50 Standard care with office based testing
Treatment: Standard Control Strategy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multi-Site, Randomized Trial of Subject-Collected Dried Blood Spot CMV Testing With Mobile Technology Support to Optimize Preemptive Therapy Late After Allogeneic HCT
- Record updated
- 25 February 2026